Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease
P. S. Winter, M. L. Ramseier, A. W. Navia, S. Saksena, H. Strouf, N. Senhaji, A. DenAdel, M. Mirza, H. H. An, L. Bilal, P. Dennis, C. S. Leahy, K. Shigemori, J. Galvez-Reyes, Y. Zhang, , M. A. Murakami
This study identifies mutation and transcriptional state compatibility in Ph+ ALL MRD, showing that targeting these interactions can overcome BCR::ABL1 independence and improve MRD monitoring.
bioRxiv · Jun 6, 2024 · PreprintCancer Biology